Northwest PK Solutions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Northwest PK Solutions is a privately-held, revenue-generating consultancy founded by Dr. Kelly Byrnes-Blake, offering deep pharmacokinetics expertise to biotech and pharmaceutical clients. The company's core business is providing high-level, hands-on PK consulting services, including study design, data analysis, and regulatory writing, to facilitate drug development programs. It leverages the founder's over 20 years of industry experience to support projects from IND-enabling studies through Phase 2 clinical trials. As a specialized service provider, it occupies a niche but critical role in the drug development ecosystem, helping smaller companies navigate complex PK challenges.

Drug Delivery

Technology Platform

Expertise-driven pharmacokinetics consulting platform encompassing study design, data analysis, interspecies scaling, dose selection, and regulatory writing for small molecule and protein therapeutics.

Opportunities

Growing demand from virtual and small biotech companies lacking in-house PK expertise, and increasing complexity of novel therapeutic modalities (e.g., biologics, cell therapies) which require sophisticated PK/PD analysis.

The essential role of PK in regulatory submissions ensures a persistent market need.

Risk Factors

Extreme concentration risk as the business is solely dependent on the founder's expertise and capacity.

Revenue is subject to volatility based on client project cycles and broader biotech funding environments.

Competition from larger CROs and other independent consultants.

Competitive Landscape

Operates in a fragmented market competing against individual independent consultants and large, full-service Contract Research Organizations (CROs). Its differentiation is high-touch, founder-direct expertise and specialization, appealing to clients who prefer a dedicated expert over a larger, less personalized CRO service model.

More companies in Digital Health & Biotech SaaS →More companies in United States →